Silver Book Fact

A recent study showed that memantine, a medicine approved to treat moderate-to-severe Alzheimer’s, significantly slows cognitive decline and reduces the need for caregiving by 45.8 hours per month.

Reference

Title
Memantine in Moderate-to-Severe Alzheimer’s Disease
Publication
N Eng J Med
Publication Date
2003
Authors
Reisberg B, Doody R, Stoffler A, Schmitt F, et al
Volume & Issue
Volume 348, Issue 14
Pages
1333-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An Alzheimer’s disease treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce Medicaid costs for people with the disease by $14 billion in 2020–from…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 total cost of care (for all payers) for all people…  
  • A treatment breakthrough that slowed the progression of Alzheimer’s disease would reduce the number of people with the disease from 2.4 million to 1.1 million in 2020, and from 6.5…  
  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.  
  • If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.